Navigation Links
QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy
Date:7/23/2009

Efficacy and Safety Study in Patients with Moderate to Severe Post-Operative Pain

SYDNEY, Australia and BEDMINSTER, N.J., July 23 /PRNewswire-FirstCall/ -- QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation of a Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. Data from this study will serve as a significant predictor of MoxDuo(TM) IV's clinical benefits and provide guidance for the design of further clinical trials leading to submission of an NDA to the US Food and Drug Administration (FDA) within the next three years.

"QRxPharma's goal is to bring to market complementary analgesic options for pain specialists, delivering greater patient tolerability and efficacy than current standards of care. MoxDuo(TM) IV is one of three Dual-Opioid(TM) products that also include immediate-release (IR) and controlled release (CR) oral formulations," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.

QRxPharma's MoxDuo(TM) products are the only combination opioids in commercial development. Extensive clinical studies have shown Dual-Opioids(TM) to provide better pain relief with significantly fewer side effects.

This double blind, active controlled study will determine: (1) whether MoxDuo(TM) IV has fewer opioid-related adverse events than morphine alone at equianalgesic doses and (2) whether the maximum analgesic effect of MoxDuo(TM) IV is superior to morphine alone.

The study is being conducted at the Cologne-Merheim Medical Center, a part of Witten/Herdecke University, and Cologne University Hospital, both in Cologne, Germany.


'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
2. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
3. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
6. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
7. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
8. Medicago initiates work on Swine Flu strain
9. Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
10. Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
11. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel ... of seed financing from friends and family investors. Proceeds ... a novel sustained-release product for ophthalmology. , "We are ... commitment to this important work," said Dr. Ken Mandell, ... many areas in which innovations in drug delivery have ...
(Date:7/29/2014)... July 30, 2014 “PharmaSphere: Emerging ... and Venture Capital Funding” report provides in-depth analysis ... private equity and venture capital segments of the ... expected to have significant impact on the future ... globally. Furthermore, the report identifies regions of the ...
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 The ... of the brain that are driving a revolution in ... a new peer-reviewed journal published by SPIE, the ... first issue coincides with the launch of the BRAIN ... features articles that lay out a vision for and ...
(Date:7/29/2014)... 29, 2014 Human Longevity, Inc. (HLI), a ... on extending the healthy, high performance human life span, ... Ph.D., an expert in machine learning and machine translation ... HLI from Google where he was Distinguished Research Scientist ... directly to HLI Co-Founder and CEO, J. Craig ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... ("Bioponic" or "the Company") (OTC: BPYT) today announced that ... to sales for the month,of January 2007., "We ... primarily,from continued success of our Flight Spray product. We ... an all-natural solution for,baby care marketed under the Gentle ...
... /Xinhua-PRNewswire/ -- China Shenghuo,Pharmaceutical Holdings, Inc. ("China ... in the research, development, manufacture, and,marketing of ... People,s Republic of China ("PRC"), today announced ... products in the United States during the,first ...
... Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned subsidiary of ... received tentative approval from the U.S. Food,and Drug ... and 40 mg (base). Nexium(R) (Esomeprazole) is the,second ... annual market sales of,$5.5 billion (IMS -- MAT: ...
Cached Biology Technology:Bioponic Phytoceuticals Announces Record Sales Increase of 40% for the Month of January 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 3Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules 2
(Date:7/30/2014)... Helsinki and the Universitat Autnoma de Barcelona have been ... have taken millions of years to occur. Through small ... teeth, induced in the laboratory, scientists have obtained teeth ... the fossil registry of rodent species which separated from ... the development of their teeth, the team from the ...
(Date:7/30/2014)... to announce its new relationship with the International College ... will partner to publish International Journal of Neuropsychopharmacology ... , Alan Frazer, Editor-in-Chief of IJNP said, ... OUP will further facilitate the goal for the ... journals within neuropsychopharmacology. The conversion of the IJNP ...
(Date:7/30/2014)... has received a pledge of $1 million from the ... Laboratory,s new Neurobehavioral Biometry Center. , The ... enable the Laboratory to develop a greater breadth and ... goal of accelerating the pace of research to improve ... a premier resource for the Laboratory and its external ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... visual centers of men and women,s brains works is ... access journal Biology of Sex Differences . Men ... stimuli, but women are better at discriminating between colors. ... male sex hormone (androgen) receptors throughout cerebral cortex, especially ...
... for up to twelve weeks could dramatically improve the ... developed the new technology are presenting their work at ... University of Warwick. Researchers at the University of ... urinary bacteria, including most strains of Proteus bacteria ...
... proportion of HIV-infected patients in the U.S. receiving effective ... and HIV-infected patients appeared to be less infectious and ... study led by researchers at the Johns Hopkins Bloomberg ... the NA-ACCORD (North American AIDS Cohort Collaboration on Research ...
Cached Biology News:The eyes have it: Men do see things differently to women 2New long-term antimicrobial catheter developed 2HIV treatment use increases in the US 2
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Edited by D. Rickwood, T.C. Ford and J.T. Steensgaard (1994) Compiles core data required by researchers carrying out any centrifugal separation, whether working with cells, organelles or macromolec...
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure Grade DAPI is greater than or equal to 98% pure by HPLC....
Biology Products: